Marker Therapeutics awarded $9.5M CPRIT grant for MT-601 in pancreatic cancer study

Marker Therapeutics, Inc.

Received $9.5M non-dilutive grant from CPRIT to support Phase 1 PANACEA study of MT-601 in metastatic pancreatic cancer.
Also received $2M NIH SBIR grant; total non-dilutive funding exceeds $30M from FDA, NIH, and CPRIT.
Clinical program initiation for MT-601 in pancreatic cancer expected in 2025.
Preliminary data from prior multiTAA-specific T cell study showed 1 CR, 3 PRs, 6 SD in 13 pancreatic cancer patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.